Trials / Completed
CompletedNCT02948777
Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Marja-Riitta Taskinen · Academic / Other
- Sex
- All
- Age
- 18 Years – 77 Years
- Healthy volunteers
- Not accepted
Summary
Postprandial lipemia is highly prevalent in type 2 diabetes subjects even with normal fasting triglyceride values. Humans are mostly in a postprandial rather than in a fasting state and therefore non-fasting triglyceride values reflect more accurately the continuous exposure of arterial wall to the substantial cholesterol load from remnant particles. Evolocumab lowers blood LDL-cholesterol. This study evaluates the effect of evolocumab on postprandial lipid metabolism in type 2 diabetes. All participants in this study receive evolocumab treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evolocumab |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2018-06-01
- Completion
- 2018-06-01
- First posted
- 2016-10-28
- Last updated
- 2021-11-03
- Results posted
- 2021-10-11
Locations
1 site across 1 country: Finland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02948777. Inclusion in this directory is not an endorsement.